Oncologist
Patient-Reported Outcomes From DESTINY-Breast04
Ueno NT, Cottone F, Dunton K, et al.
This report details patient-reported outcomes from DESTINY-Breast04, focusing on the hormone receptor-positive cohort. Trastuzumab deruxtecan maintained global health status/quality of life scores despite a longer treatment course versus standard chemotherapy, and delayed definitive deterioration versus the physician’s choice of chemotherapy.
Previous Article
- • Delphi Consensus for Managing Adverse Events in Patients With Metastatic Triple-Negative Breast Cancer Receiving Sacituzumab Govitecan
- • The Safety and Effectiveness of Palbociclib in Clinical Practice
- • Determinants of HER2-Targeted Therapy Use in Metastatic HR-/HER2+ Breast Cancer
- • Equity of Care Across Metastatic Breast Cancer Treatment
- • Tumor Growth Rate and Survival in Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
- • Patient-Reported Outcomes From DESTINY-Breast04
- • Prognostic Significance of TILs in HER2+ Metastatic Breast Cancer
- • Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer
- • Animal Models in Metastatic Breast Cancer Immunotherapy Research
- • PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders
- • Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
- • Imlunestrant Monotherapy: Phase 1a/1b EMBER Study
- • Characterization of Imlunestrant as an Oral, Brain-Penetrant SERD
- • Pharmacodynamics from EMBER-2
- • Imlunestrant: First Approval
- • Imlunestrant Overcomes ESR1 Mutant Resistance in ER-Positive Breast Cancer
- • ESR1 Mutations in Breast Cancer
